TELO

Telomir Pharmaceuticals, Inc. (TELO) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Telomir Pharmaceuticals, Inc. is a pre-clinical stage biopharmaceutical company developing TELOMIR-1, a novel small molecule designed to lengthen telomeres to potentially treat age-related conditions in humans and animals. The reporting period covers the three and six months ended June 30, 2024. The company completed its Initial Public Offering (IPO) on February 13, 2024, raising approximately $5.8 million in net proceeds. As of August 13, 2024, there were 29,609,814 shares of common stock outstanding.

Key Financial Metrics

Expense Breakdown (Six Months 2024):

• General and Administrative (G&A): $1,621,237
• Research and Development (R&D): $1,398,824
• Related Party Travel Costs: $370,500
• Interest Expense: $4,338,542 (Primarily non-cash amortization of deferred financing costs)

Material Changes vs. Prior Period

• Revenue: No revenue generated in either period as the company remains pre-clinical.
• Net Loss: Net loss increased significantly to $7.7 million from $2.0 million year-over-year. This increase is largely driven by a one-time non-cash interest expense of $4.3 million related to the amortization of deferred financing costs from warrants issued in 2023.
• Operating Expenses: G&A expenses surged from $0.1 million to $1.6 million due to new payroll costs for management and consultants following the IPO. R&D expenses increased moderately from $1.1 million to $1.4 million.
• Liquidity: Cash balances improved dramatically from $14,629 in June 2023 to $1.88 million in June 2024, primarily due to $5.8 million in net IPO proceeds.
• Debt: The related party line of credit with Bay Shore Trust was paid in full during the first quarter of 2024 and is no longer available.

Guidance, Outlook, and Risks

Outlook and Guidance: Management expects expenses to increase substantially as the company advances pre-clinical activities and initiates clinical trials. The Investigational New Drug (IND) application is anticipated to be filed with the FDA in the first half of 2025. The company currently expects its cash on hand will not be sufficient to fund operations through Q1 2025 without additional financing.

Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for at least 12 months following the issuance of the financial statements due to recurring losses and insufficient cash.

Subsequent Events (August 2024):

• Leadership Change: Dr. Christopher Chapman, Chairman and CEO, passed away on August 8, 2024.
• Board Restructuring: Three directors resigned, and four new directors were appointed. Erez Aminov was appointed as the new CEO and Chairman.
• Employment Agreement: Mr. Aminov entered into an employment agreement with a base salary of $275,000 per year and specific severance provisions.

Risks: Key risks include the inability to obtain regulatory approval, failure to secure additional funding, and the inherent uncertainties of pre-clinical drug development. Disclosure controls and procedures were deemed ineffective as of June 30, 2024, though remediation efforts are underway.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise, as management projects cash insufficiency by Q1 2025.
• Non-Cash Charges: Confirm the impact of the $4.3 million non-cash interest expense on the reported net loss to understand the true cash burn rate.
• Related Party Transactions: Review the terms of the license agreement with MIRALOGX (8% royalty) and the nature of related party travel and rental costs.
• Leadership Stability: Assess the experience and track record of the new CEO, Erez Aminov, and the newly appointed board members following the sudden departure of the previous leadership.
• Internal Controls: Monitor the progress of remediation efforts regarding the ineffective disclosure controls and procedures.